Is This Growth Stock Undervalued?
Biotech company Bluebird Bio (NASDAQ: BLUE) is currently riding high. Over the past month, the gene-editing specialist has earned approval for not one but two innovative treatments in the U.S. That is a feat very few gene-editing experts have achieved. Despite these accomplishments, Bluebird is still a tiny company with a market cap of just $475 million.
It seems the market isn't putting much faith into the biotech's approved programs, but could that be a mistake? Let's consider whether Bluebird's shares are a steal at current levels.
Source Fool.com
